Back to search results

First-in-Human Trial of VBC106 for Advanced Solid Tumors

This is a first-in-human (FIH) study testing a new drug called VBC106 in people with advanced solid tumors. The main goals are to find a safe dose of VBC106 and to see how well people tolerate it. Researchers will also look at any side effects (adverse events) that happen. You might be able to join if you are 18 years or older and have an advanced solid tumor. This study is currently recruiting 260 participants, but the current status is unclear. There are no specific biomarkers or mechanisms of action mentioned for this drug in the trial details.

Study design
This is a Phase 1/2a, open-label study, meaning both you and your doctors will know which treatment you are receiving. It plans to enroll 260 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
You will be monitored for serious adverse events and adverse events from the time you give informed consent until 30 days after your last dose of VBC106.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07686068

First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors

Not Yet Recruiting
PHASE1Ages 18+InterventionalTreatment
VelaVigo Bio Inc
~260 participants
Updated 2026-07-09 on ClinicalTrials.gov
What's tested:VBC106

At a glance

Recruiting sites
0 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of dose-limiting toxicities (DLT) as defined in the protocol
Measured over (DLT)From time of first dose of VBC106 to end of DLT period (approximately 21 days)
+2 more outcomes measured

Conditions

Participants With Advanced Solid Tumor Malignancies

Explore related trials

Solid Neoplasm

NCT07686068

Where you'd take part

This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Icon Cancer Centre Wesley

    Brisbane, Queensland, Australiastudy coordinator listed

  • NEXT Oncology Houston

    Houston, Texasstudy coordinator listed

  • NEXT Oncology Virginia

    Fairfax, Virginiastudy coordinator listed

  • START Mountain Region, LLC.

    West Valley City, Utahstudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Feng Guo
[email protected]
17368707951
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

1\. The participant or the participant's legally acceptable representative is willing and able to provide a written ICF before initiating any trial procedure.
2\. Histologically or cytologically confirmed unresectable advanced/metastatic solid tumor that has relapsed or progressed on or after standard systemic treatments, or is intolerable with standard treatment, or standard therapies are not appropriate or not safe in the opinion of the Investigator or refused by the participant.
3\. At least one measurable lesion as assessed according to RECIST v1.1 criteria for participants with non-pleural mesothelioma or other solid tumors and modified RECIST(mRECIST) for participants with malignant pleural mesothelioma.
4\. Male or female adults (defined as ≥ 18 years of age)
5\. ECOG performance status 0-1
6\. Has LVEF ≥ 50% by either ECHO or MUGA within 28 days before enrollment.
7\. Life expectancy greater than 12 weeks
8\. Archived tumor tissue sample available or able to undergo a fresh biopsy collection.
9\. Adequate organ and bone marrow function

What this trial measures

  • Incidence of dose-limiting toxicities (DLT) as defined in the protocol(DLT)From time of first dose of VBC106 to end of DLT period (approximately 21 days)

    Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol

  • Incidence of Serious Adverse EventsFrom time of Informed Consent to 30 days post last dose of VBC106

    Number of patients with serious adverse events by system organ class and preferred term

  • Incidence of Adverse Events (AEs)From time of Informed Consent to 30 days post last dose of VBC106

    Number of patients with adverse events by system organ class and preferred term